Great Elm Capital Group Inc

Great Elm Capital Group Inc

  • Price (USD)2.85
  • Today's Change-0.08 / -2.73%
  • Shares traded66.94k
  • 1 Year change-16.91%
  • Beta0.8120
Data delayed at least 15 minutes, as of Feb 27 2020 20:55 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Great Elm Capital Group, Inc. is a holding company. The Company makes investments in businesses and assets in various industries. The Company's investment for long-term value creation is in the asset management business. The Company continues to explore other opportunities in the investment management business, including other business development companies (BDCs) that trade at a discount to their net asset value. The Company intends to build a diversified investment company consisting of three business lines: investment management, financial products and merchant banking. It is embarking on a program of creating bespoke financial products and creating a pipeline of acquisition opportunities. The Company also seeks to build a business across three verticals: investment management, real estate and operating companies. Through its subsidiary, Great Elm Capital Management, Inc., the Company provides investment advisory and maintenance services.

  • Revenue in USD (TTM)61.09m
  • Net income in USD-5.49m
  • Incorporated1994
  • Employees328.00
  • Location
    Great Elm Capital Group Inc800 South St Ste 230WALTHAM 02453-1445United StatesUSA
  • Phone+1 (617) 375-3024
  • Fax+1 (302) 655-5049
  • Websitehttp://www.greatelmcap.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
STRATA Skin Sciences Inc30.65m-3.44m52.32m105.00--1.8137.341.71-0.1096-0.10960.98070.8770.65423.779.62291,914.30-7.34-24.03-8.97-29.3062.6949.44-11.22-39.051.67-6.380.2064---6.01123.44-266.72---19.42--
Vuzix Corp6.70m-24.36m53.67m80.00--1.60--8.01-0.8475-0.84750.23141.010.17740.82476.2083,720.00-59.47-89.85-64.88-113.823.896.61-335.29-380.927.06--0.00--46.1727.64-11.00--46.96--
Neuronetics Inc60.94m-27.63m54.97m191.00--1.01--0.902-1.52-1.523.362.920.5435.379.50319,031.40-24.62---29.53--75.58---45.35--4.23-6.900.3629--30.53---50.05------
Apollo Endosurgery Inc53.91m-38.59m55.50m215.00--5.58--1.03-1.77-1.772.470.47520.58642.245.62250,725.60-41.98-41.38-54.50-53.3249.94---71.59-60.242.33-7.960.8415---5.3750.10-67.77--49.09--
ConforMIS Inc79.59m-32.92m57.03m268.00--2.85--0.7166-0.5239-0.52391.260.2910.99733.857.19296,973.90-41.24-50.43-50.60-57.5947.6839.02-41.36-70.972.43-5.240.4941--14.9421.0119.09---0.2591--
Sensus Healthcare Inc27.26m-1.70m60.01m48.00--2.14--2.20-0.106-0.1061.671.700.7774.202.01---4.84-7.81-5.89-10.3464.4065.10-6.24-8.074.79------3.1636.2315.96------
Item 9 Labs Corp-100.00bn-100.00bn61.42m65.00--11.15----------0.0897-----------121.75---326.28--42.76---238.79----0.4849--251.9694.01-1,283.76--147.97--
Allied Healthcare Products Inc31.29m-2.24m62.29m243.00--6.39--1.99-0.5584-0.55847.802.431.943.299.86---13.88-8.93-20.63-10.8817.7719.09-7.16-5.520.644-51.950.0919---7.05-2.91-89.75------
Second Sight Medical Products Inc4.65m-34.58m66.50m123.00--4.66--14.31-2.80-2.800.35530.91730.26331.496.3837,796.75-195.83-132.99-335.67-188.9521.947.25-743.86-487.322.66--0.00---13.4134.53-23.07---7.90--
Pro-Dex Inc29.06m3.97m69.88m97.0018.813.9215.562.400.95930.96127.004.601.103.018.96299,577.3015.0314.5417.1917.7135.9632.1913.6410.973.3161.600.2046--20.9520.24137.93--55.25--
Great Elm Capital Group Inc61.09m-5.49m72.45m328.00--1.2812.971.19-0.2163-0.0582.412.230.342615.458.30186,243.90-3.45-10.51-4.13-12.7257.76---10.08-92.611.42-0.53510.5904--762.34--37.46--154.30--
Clearpoint Neuro Inc11.22m-5.54m78.00m33.00--17.01--6.95-0.3835-0.38350.83650.30111.131.439.65---56.00-68.39-80.61-117.2065.8361.99-49.39-97.511.77-4.810.3112--52.5425.4910.12--27.19--
SANUWAVE Health, Inc.1.15m-9.74m83.24m14.00------72.42-0.0559-0.05590.0066-0.05420.97082.1811.0082,097.86-822.76-370.16----49.4865.28-847.52-595.290.0459-3.40----150.5118.25-110.03------
PAVmed Inc0.00-17.31m88.96m9.00---------0.6259-0.62590.00-0.05160.00----0.00-255.52---1,995.16-------------6.752.17-------80.33------
BioSig Technologies Inc0.00-25.12m90.26m----6.38-----1.31-1.310.000.5550.00-------227.70-895.19-254.84--------------0.00-------66.48--92.24--
Data as of Feb 27 2020. Currency figures normalised to Great Elm Capital Group Inc's reporting currency: US Dollar USD

Institutional shareholders

56.31%Per cent of shares held by top holders
HolderShares% Held
Northern Right Capital Management LPas of 31 Dec 20192.40m9.46%
Imperial Capital Asset Management LLCas of 26 Aug 20192.32m9.14%
MAST Capital Management LLCas of 26 Aug 20192.00m7.88%
Cove Street Capital LLCas of 31 Dec 20191.74m6.85%
Kingdon Capital Management LLCas of 31 Dec 20191.27m4.99%
The Vanguard Group, Inc.as of 31 Dec 20191.15m4.53%
Arbiter Partners Capital Management LLCas of 31 Dec 20191.15m4.53%
Renaissance Technologies LLCas of 31 Dec 2019813.93k3.21%
Punch & Associates Investment Management, Inc.as of 31 Dec 2019772.00k3.04%
Royce & Associates LPas of 31 Dec 2019682.25k2.69%
More ▼
Data from 26 Aug 2019 - 31 Dec 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.